Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III Long-term Extension Study of S-877503 in Pediatric ADHD
jRCT2080222071Phase 3
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Shionogi & Co., Ltd.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2080222071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222071.